

STAMPEDE Abiraterone Latitude Criteria (De-novo patients)	ADT Alone	ADT + AAP				
	No. of events/ No. of patients		Adjusted HR (95% CI)			Interaction between metastatic subgroups p-value
Overall Survival						
Overall	192/431	130/428			0.59 (0.47-0.74)	
Low	57/202	39/190			0.64 (0.42-0.97)	
High	135/229	91/238			0.52 (0.40-0.69)	0.40
Failure Free Survival						
Overall	343/431	182/428			0.30 (0.25-0.37)	
Low	143/202	50/190			0.22 (0.16-0.31)	
High	200/229	132/238			0.31 (0.25-0.39)	0.21
Skeletal Related Events						
Overall	159/431	90/428			0.47 (0.36-0.60)	
Low	45/202	16/190			0.32 (0.18-0.57)	
High	114/229	74/238			0.47 (0.35-0.63)	0.26
Progression Free Survival						
Overall	258/431	150/428			0.44 (0.36-0.53)	
Low	93/202	36/190			0.32 (0.22-0.47)	
High	165/229	114/238			0.46 (0.36-0.58)	0.15
Prostate Cancer Specific Death						
Overall	170/431	109/428			0.57 (0.44-0.72)	
Low	48/202	25/190			0.48 (0.29-0.80)	
High	122/229	84/238			0.56 (0.41-0.74)	0.64

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2

Favours ADT + AAP



Favours ADT